BioSpace News Archive

Shield Diagnostics, an Andreessen Horowitz-backed biotechnology company tackling antibiotic resistance by bringing precision medicine to infectious disease, announced today that it has appointed David Esposito to its Board of Directors.

Through the Innovation Superclusters Initiative, the Government of Canada is taking immediate and targeted action to build on Canada’s existing strengths to help our companies and their workers get ahead in the global innovation race

PER® Global, a worldwide leading resource for continuing medical education (CME), will host the live CME-accredited Medical Crossfire®: Leveraging the Lung Cancer Team in Stage III NSCLC With Immuno-Oncology Strategies, adjunct to the IASLC 2019 World Conference on Lung Cancer.

Crucial differences discovered in human and mice brain cells could explain why many drugs that work in the lab don’t work in us

eSimplify, a market-leading provider of Family Practice healthcare analytics that enables small and medium sized Family Practice and Internal Medicine Groups to increase revenue, improve quality scores, and enhance patient care is proud to announce a national distribution agreement with ChartSpan.

Conagen, a vertically integrated synthetic biology company located in Boston’s biotech corridor, announced today that it has acquired a fermentation-based technology for the production of therapeutically useful glycoproteins.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the filing of a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) to add an indication for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC).

XTANDI Supplemental New Drug Application (sNDA) Seeks to Add an Indication for Men with Prostate Cancer that Has Spread but Is Sensitive to Hormone Therapy

AmeriHealth Caritas New Hampshire and SolutionHealth announced they have signed a contract that will allow AmeriHealth Caritas New Hampshire members to receive care from SolutionHealth’s hospitals, physicians, and other affiliated providers.

Chrysalis BioTherapeutics, Inc. today announced that the US Food and Drug Administration (FDA) Office of Orphan Product Development and the European Medicines Agency (EMA) have granted Orphan Drug Designation (ODD) to the company’s lead compound, TP508 (rusalatide acetate) for the treatment of acute radiation syndrome (ARS).